5.75

13.79% -0.92

After Hours: 6.50 0.75 +13.04%

Aldeyra Therapeutics Inc (ALDX)

Overview News Price History Option Chain Financials Discussions Forecast

Aldeyra Therapeutics Inc stock is traded at $5.75, with a volume of 2.96M. It is down -13.79% in the last 24 hours and up +12.52% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Previous Close:

$6.67

Open:

$6.53

24h Volume:

2.96M

Relative Volume:

5.52

Market Cap:

$356.76M

Revenue:

Net Income/Loss:

$-44.80M

P/E Ratio:

-7.6667

EPS:

-0.75

Net Cash Flow:

$-30.67M

1W Performance:

-13.01%

1M Performance:

+12.52%

6M Performance:

+6.68%

1Y Performance:

+75.84%

1-Day Range:

$5.62

$6.55

1-Week Range:

$5.62

$6.8094

52-Week Range:

$3.10

$7.20

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name

Aldeyra Therapeutics Inc

Sector

Healthcare (1164)

Industry

Biotechnology (681)

Phone

781-761-4904

Address

131 HARTWELL AVENUE, LEXINGTON, MA

Employee

Twitter

@aldeyraaldx

Next Earnings Date

2024-11-18

Latest SEC Filings

ALDX's Discussions on Twitter

Compare ALDX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALDX Aldeyra Therapeutics Inc	5.75	356.76M	0	-44.80M	-30.67M	-0.75
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform
Apr-02-24	Resumed	H.C. Wainwright	Buy
Apr-27-22	Resumed	H.C. Wainwright	Buy
Feb-08-21	Initiated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Oct-30-20	Initiated	Jefferies	Buy
Oct-16-20	Initiated	BTIG Research	Buy
Sep-22-20	Initiated	Alliance Global Partners	Buy
May-12-20	Initiated	Oppenheimer	Outperform
Dec-04-18	Initiated	Citigroup	Buy
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy
Sep-26-16	Initiated	H.C. Wainwright	Buy
Jul-01-16	Initiated	Stifel	Buy
Jul-01-15	Initiated	Canaccord Genuity	Buy
Mar-25-15	Initiated	Chardan Capital Markets	Buy
Mar-20-15	Reiterated	H.C. Wainwright	Buy
Nov-18-14	Initiated	H.C. Wainwright	Buy
Jun-19-14	Initiated	Aegis Capital	Buy

View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

09:05 AM

Does Candel Therapeutics Inc (NASDAQ: CADL) Still Need To Convince Analysts? - Stocks Register

09:05 AM

Does QXO Inc (NYSE: QXO) Still Look Hot This Week? - Stocks Register

09:05 AM

Mar 28, 2025

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 28, 2025

Raymond James Financial Inc. Invests $3.63 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Mar 28, 2025

Mar 27, 2025

Trend Tracker for (ALDX) - news.stocktradersdaily.com

Mar 27, 2025

Mar 26, 2025

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Above 50-Day Moving Average – Here’s Why - Defense World

Mar 26, 2025

Mar 22, 2025

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 22, 2025

Mar 20, 2025

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX - Business Wire

Mar 20, 2025

Mar 17, 2025

BTIG maintains Aldeyra stock Buy rating, $11 target By Investing.com - Investing.com Canada

Mar 17, 2025

Aldeyra Therapeutics Beats Investor Suit Over Eye Drug Misses - Bloomberg Law News

Mar 17, 2025

(ALDX) On The My Stocks Page - Stock Traders Daily

Mar 17, 2025

Mar 14, 2025

Biotech Wins Dismissal Of Investor Fraud Claims - Law360

Mar 14, 2025

Mar 11, 2025

ALDX stock touches 52-week high at $6.93 amid robust gains - Investing.com Australia

Mar 11, 2025

ALDX stock touches 52-week high at $6.93 amid robust gains By Investing.com - Investing.com South Africa

Mar 11, 2025

Tech Stocks Defying Market Volatility: Meet the Pioneers of Tomorrow’s Economy - DSA

Mar 11, 2025

High Growth Tech Stocks To Watch In The US March 2025 - Simply Wall St

Mar 11, 2025

Mar 10, 2025

Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference - Business Wire

Mar 10, 2025

Aldeyra Therapeutics CEO Scheduled for Fireside Chat at Major Healthcare Conference - Stock Titan

Mar 10, 2025

Mar 07, 2025

Aldeyra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 05, 2025

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha

Mar 05, 2025

Mar 04, 2025

Chronic Cough Market Expected to rise, 2034 | Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., expected to drive market - Barchart

Mar 04, 2025

Chronic Cough Market Expected to rise, 2034 | Merck & Co, Kyorin - openPR

Mar 04, 2025

Aldeyra Therapeutics (NASDAQ:ALDX) Receives Buy Rating from HC Wainwright - Defense World

Mar 04, 2025

Mar 03, 2025

Aldeyra Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

Mar 03, 2025